TOP
Events & Outreach
R-CCS Cafe
The 228th R-CCS Cafe - part 1
The 228th R-CCS Cafe - part 1
JapaneseTitle
Molecular Dynamics Simulations and Drug Design
Date | Mon, Mar 7, 2022 |
---|---|
Time | 4:00 pm - 4:20 pm (5 pm - 5:20 pm Discussion, 5:20 pm - Free discussion (optional)) |
City | Online |
Place | Online seminar on BlueJeans
|
Language | Presentation Language: English Presentation Material: English |
Speakers |
Mitsunori Ikeguchi Unit Leader, Molecular Design Computational Intelligence Unit ![]() |
Abstract
How do drugs work? Most drugs bind to the active site of the target protein. The three-dimensional structure of the target protein is not static, but dynamic and fluctuating. Therefore, when a drug binds to a protein, it may induce conformational changes of the protein. Compounds called agonists change the structure of the protein upon binding and transmit the information downstream. On the other hand, compounds called antagonists do not change the function of the protein when they bind to it. Agonists and antagonists sometimes have similar chemical structures, and the protein recognizes the subtle differences and changes its response. Will high performance computing be able to identify such differences? I would like to present a computational study that examined the differences in response to agonist and antagonist binding to the vitamin D receptor, which is involved in osteoporosis and other diseases.
Important Notes
- Please turn off your video and microphone when you join the meeting.
- The broadcasting may be interrupted or terminated depending on the network condition or any other unexpected event.
- The program schedule and contents may be modified without prior notice.
- Depending on the utilized device and network environment, it may not be able to watch the session.
- All rights concerning the broadcasted material will belong to the organizer and the presenters, and it is prohibited to copy, modify, or redistribute the total or a part of the broadcasted material without the previous permission of RIKEN.
(Mar 4, 2022)